Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Orexo AB (publ) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ORXOY
Over the counter
2834
www.orexo.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Orexo AB (publ)
Orexo AB (ORXOY) Q4 2024 Earnings Call Highlights: Strong EBITDA and Strategic Wins Amid Challenges
- Feb 7th, 2025 7:09 am
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
- Jan 10th, 2025 1:24 pm
Abera and Orexo partner for vaccine powder formulations
- Dec 18th, 2024 3:34 pm
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
- Dec 17th, 2024 7:31 am
Orexo initiates new study of OX640 in participants with allergic rhinitis
- Oct 25th, 2024 1:28 pm
Orexo AB (ORXOY) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
- Oct 25th, 2024 7:07 am
Orexo Interim Report Q3 2024
- Oct 24th, 2024 7:34 am
Orexo´s Nomination Committee for the Annual General Meeting 2025
- Oct 4th, 2024 6:26 am
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
- Sep 3rd, 2024 7:45 am
FDA issues CRL to Orexo’s NDA for opioid overdose medication
- Jul 17th, 2024 8:52 am
Orexo Q2 2024 Interim Report
- Jul 17th, 2024 6:31 am
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
- Jul 16th, 2024 8:04 pm
OTC Markets Hosts Virtual Investor Presentation with Nikolaj Sorensen, President and CEO of Orexo AB, and Brad Sorensen, Senior Analyst at Zacks SCR
- Jul 10th, 2024 1:36 pm
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
- Jul 10th, 2024 6:34 am
Orexo: invitation to presentation of the Q2 2024 Interim Report
- Jul 8th, 2024 12:09 pm
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
- Jun 21st, 2024 12:35 pm
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
- Jun 18th, 2024 12:35 pm
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- May 10th, 2024 12:43 pm
Orexo Q1 2024 Interim Report
- May 8th, 2024 6:27 am
Report from Orexo AB's annual general meeting, 26 April 2024
- Apr 26th, 2024 4:12 pm
Scroll